Atara biotherapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 52,474 restricted stock units of atara's common stock to 15 newly hired employees and stock options to purchase an aggregate of 5,618 shares of atara's common stock to one such newly hired emp
ATRA Ratings Summary
ATRA Quant Ranking